PE20070339A1 - Derivados de 5-piridinil-1-azabiciclo[3.2.1]octano como ligandos de los receptores nicotinicos y su preparacion - Google Patents

Derivados de 5-piridinil-1-azabiciclo[3.2.1]octano como ligandos de los receptores nicotinicos y su preparacion

Info

Publication number
PE20070339A1
PE20070339A1 PE2006000974A PE2006000974A PE20070339A1 PE 20070339 A1 PE20070339 A1 PE 20070339A1 PE 2006000974 A PE2006000974 A PE 2006000974A PE 2006000974 A PE2006000974 A PE 2006000974A PE 20070339 A1 PE20070339 A1 PE 20070339A1
Authority
PE
Peru
Prior art keywords
azabicycle
pyridinyl
octane
ligands
derivatives
Prior art date
Application number
PE2006000974A
Other languages
English (en)
Inventor
Frederic Galli
Odile Leclerc
Julien Vache
Alistair Lochead
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36273387&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20070339(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of PE20070339A1 publication Critical patent/PE20070339A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

REFERIDA A UN COMPUESTO AZABICICLICO DE FORMULA (I), DONDE R ES PIRAZOLILO, IMIDAZOLILO, TRIAZOLILO, OXAZOLILO, ENTRE OTROS, OPCIONALMENTE SUSTITUIDOS CON HALOGENO, ALQUILO C1-C6, ALCOXI C1-C6, CIANO, ENTRE OTROS; EL ENLACE CARBONO - CARBONO ENTRE LAS POSICIONES 3 Y 4 DEL CICLO AZABICICLOOCTANO ES SIMPLE O DOBLE. SON COMPUESTOS PREFERIDOS: 5-[2-(1-METIL-1H-PIRAZOL-4-IL)PIRIDIN-5-IL]-1-AZABICICLO[3.2.1]-OCTANO, 5-[2-(1H-PIRAZOL-4-IL)PIRIDIN-5-IL]-1-AZABICICLO[3.2.1]-OCTANO, 5-[2-(1H-PIRAZOL-4-IL)PIRIDIN-5-IL]-1-AZABICICLO[3.2.1]-OCT-3-ENO, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS TIENEN AFINIDAD POR LOS RECEPTORES NICOTINICOS Y TIENEN SELECTIVIDAD POR LOS RECEPTORES NICOTINICOS QUE CONTIENEN LA UNIDAD ALFA 7 Y SON UTILES EN EL TRATAMIENTO DE LA ENFERMEDAD DE PARKINSON, ESQUIZOFRENIA, TRASTORNOS BIPOLARES, DEPRESION, ANSIEDAD, ENTRE OTROS
PE2006000974A 2005-08-12 2006-08-10 Derivados de 5-piridinil-1-azabiciclo[3.2.1]octano como ligandos de los receptores nicotinicos y su preparacion PE20070339A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0508528A FR2889701B1 (fr) 2005-08-12 2005-08-12 Derives de 5-pyridinyl-1-azabicyclo[3.2.1]octane, leur preparation en therapeutique.

Publications (1)

Publication Number Publication Date
PE20070339A1 true PE20070339A1 (es) 2007-04-18

Family

ID=36273387

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000974A PE20070339A1 (es) 2005-08-12 2006-08-10 Derivados de 5-piridinil-1-azabiciclo[3.2.1]octano como ligandos de los receptores nicotinicos y su preparacion

Country Status (41)

Country Link
US (2) US7863290B2 (es)
EP (1) EP1915375B1 (es)
JP (1) JP5164841B2 (es)
KR (1) KR101299339B1 (es)
CN (1) CN101238125B (es)
AT (1) ATE444964T1 (es)
AU (1) AU2006281341B2 (es)
BR (1) BRPI0614623A2 (es)
CA (1) CA2617828C (es)
CR (1) CR9625A (es)
CY (1) CY1109717T1 (es)
DE (1) DE602006009668D1 (es)
DK (1) DK1915375T3 (es)
DO (1) DOP2006000180A (es)
EA (1) EA014023B1 (es)
EC (1) ECSP088170A (es)
ES (1) ES2332472T3 (es)
FR (1) FR2889701B1 (es)
GT (1) GT200600368A (es)
HK (1) HK1120788A1 (es)
HN (1) HN2008000090A (es)
HR (1) HRP20090677T1 (es)
IL (1) IL188796A (es)
JO (1) JO2583B1 (es)
MA (1) MA30200B1 (es)
ME (1) ME01750B (es)
MX (1) MX2008001968A (es)
MY (1) MY147846A (es)
NO (1) NO20081151L (es)
NZ (1) NZ565149A (es)
PE (1) PE20070339A1 (es)
PL (1) PL1915375T3 (es)
PT (1) PT1915375E (es)
RS (1) RS51068B (es)
SI (1) SI1915375T1 (es)
TN (1) TNSN07472A1 (es)
TW (1) TWI324158B (es)
UA (1) UA92917C2 (es)
UY (1) UY29744A1 (es)
WO (1) WO2007020344A1 (es)
ZA (1) ZA200800958B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2912404B1 (fr) 2007-02-09 2009-04-10 Sanofi Aventis Sa Derives d'azabicycloalkane,leur preparation et leur application en therapeutique.
GB0817424D0 (en) 2008-09-24 2008-10-29 Medivir Ab Protease inhibitors
JP2017114765A (ja) * 2014-04-25 2017-06-29 大正製薬株式会社 トリアゾリルで置換されたヘテロアリール化合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817679A (en) * 1993-04-01 1998-10-06 University Of Virginia 7-Azabicyclo 2.2.1!-heptane and -heptene derivatives as cholinergic receptor ligands
EP0664293A1 (en) * 1993-12-24 1995-07-26 Duphar International Research B.V 2-Phenyl-7-azabicycloheptanes and 6-phenyl-8-azabicyclo
CN1157392C (zh) * 1997-05-30 2004-07-14 神经研究公司 在尼古丁ach受体上作为胆碱能配体的8-氮杂双环(3,2,1)辛-2-烯以及辛烷衍生物
FR2834511B1 (fr) * 2002-01-07 2004-02-13 Sanofi Synthelabo Derives de 5-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
DE602006009668D1 (de) 2009-11-19
NO20081151L (no) 2008-05-13
TNSN07472A1 (en) 2009-03-17
ES2332472T3 (es) 2010-02-05
JP2009505971A (ja) 2009-02-12
ME01750B (me) 2010-10-31
UY29744A1 (es) 2007-03-30
CN101238125A (zh) 2008-08-06
EP1915375A1 (fr) 2008-04-30
PL1915375T3 (pl) 2010-03-31
JO2583B1 (en) 2011-02-27
JP5164841B2 (ja) 2013-03-21
CN101238125B (zh) 2012-07-04
ZA200800958B (en) 2009-04-29
WO2007020344A1 (fr) 2007-02-22
CR9625A (es) 2008-04-10
IL188796A0 (en) 2008-08-07
US20080146608A1 (en) 2008-06-19
GT200600368A (es) 2007-07-06
FR2889701A1 (fr) 2007-02-16
DOP2006000180A (es) 2007-02-28
ECSP088170A (es) 2008-03-26
CA2617828C (fr) 2014-03-11
US20110077264A1 (en) 2011-03-31
AU2006281341A1 (en) 2007-02-22
DK1915375T3 (da) 2010-02-15
KR101299339B1 (ko) 2013-08-26
IL188796A (en) 2012-09-24
US7863290B2 (en) 2011-01-04
RS51068B (sr) 2010-10-31
HN2008000090A (es) 2010-08-19
AU2006281341B2 (en) 2012-04-19
FR2889701B1 (fr) 2007-10-05
BRPI0614623A2 (pt) 2011-04-12
TW200740810A (en) 2007-11-01
HK1120788A1 (es) 2009-04-09
MA30200B1 (fr) 2009-02-02
SI1915375T1 (sl) 2010-01-29
HRP20090677T1 (hr) 2010-01-31
CA2617828A1 (fr) 2007-02-22
PT1915375E (pt) 2009-11-26
NZ565149A (en) 2011-05-27
MY147846A (en) 2013-01-31
MX2008001968A (es) 2008-03-26
UA92917C2 (uk) 2010-12-27
EA200800575A1 (ru) 2008-06-30
ATE444964T1 (de) 2009-10-15
EP1915375B1 (fr) 2009-10-07
CY1109717T1 (el) 2014-08-13
KR20080033378A (ko) 2008-04-16
EA014023B1 (ru) 2010-08-30
US8541440B2 (en) 2013-09-24
TWI324158B (en) 2010-05-01

Similar Documents

Publication Publication Date Title
UY29857A1 (es) Derivados de la 4-amino-quinazolina, su preparación y su aplicación en terapéutica.
UY28855A1 (es) Derivados de la 1-amino-ftalazina su preparación y su uso en terapia
BRPI0511933A (pt) derivados de quinazolinona úteis como antagonistas de vanilóide
EA200970149A1 (ru) Производные n-(аминогетероарил)-1h-индол-2-карбоксамидов, их получение и их применение в терапии
NO20075169L (no) Nye imidazo (1,5-A)pyndindenvater, fremgangsmate for fremstilling og farmasoytiske sammensetninger som inneholder samme.
UY30842A1 (es) Derivados de n-(amino-heteroaril)-1h-pirrolopiridin-2-carboxamidas, su preparacion y su aplicacion en terapéutica
ECSP067111A (es) Derivados de pirido-pirimidina, su preparación, su aplicación en terapéutica
DE602007009839D1 (de) Imidazo ä1,2-aüpyridin-2-carboxamid-derivate, herstellungsverfahren und ihre verwendung für therapeutika
ECSP077402A (es) Derivados de 2-amido-4-feniltiazol, su preparación y su aplicación en terapéutica
UY29859A1 (es) Derivados de 1-amino-isiquinolina,su preparación y su aplicación terapéutica
ATE446089T1 (de) 2-benzoyl-imidazopyridin-derivate, herstellungsverfahren und ihre verwendung für therapeutika
EA200800264A1 (ru) Производные пиразоло[3,4-d]азепина как антагонисты н3-рецепторов гистамина
NO20080705L (no) Aminoaryl Sulphonamide Derivatives as functional 5-HT6 Ligands
PE20070339A1 (es) Derivados de 5-piridinil-1-azabiciclo[3.2.1]octano como ligandos de los receptores nicotinicos y su preparacion
TW200800983A (en) 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase
UY29858A1 (es) Derivados de la 1-amino-ftalazina sustituida, su preparación y su aplicación en terapéutica
TH91111B (th) สารประกอบจำลองไลซีดัดแปร

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed